Amin Anish, Houmsse Aseel, Ishola Abiodun, Tyler Jaret, Houmsse Mahmoud
Department of Cardiovascular Medicine, The Ohio State University Medical Center, Columbus, Ohio, USA.
Avicenna J Med. 2016 Jan-Mar;6(1):8-16. doi: 10.4103/2231-0770.173580.
Atrial fibrillation (AF) is the most commonly encountered arrhythmia in clinical practice. Aging populations coupled with improved outcomes for many chronic medical conditions has led to increases in AF diagnoses. AF is also known to be associated with an increased risk of adverse events such as transient ischemic attack, ischemic stroke, systemic embolism, and death. This association is enhanced in select populations with preexisting comorbid conditions such as chronic heart failure. The aim of this review is to highlight the advances in the field of cardiology in the management of AF in both acute and long-term settings. We will also review the evolution of anticoagulation management over the past few years and landmark trials in the development of novel oral anticoagulants (NOACs), reversal agents for new NOACs, nonpharmacological options to anticoagulation therapy, and the role of implantable loop recorder in AF management.
心房颤动（AF）是临床实践中最常遇到的心律失常。人口老龄化以及许多慢性疾病治疗效果的改善导致AF诊断率上升。AF还与不良事件风险增加有关，如短暂性脑缺血发作、缺血性中风、全身性栓塞和死亡。在患有慢性心力衰竭等合并症的特定人群中，这种关联更为明显。本综述的目的是强调心脏病学领域在急性和长期情况下AF管理方面的进展。我们还将回顾过去几年抗凝管理的演变以及新型口服抗凝药（NOACs）开发中的标志性试验、新型NOACs的逆转剂、抗凝治疗的非药物选择以及植入式环路记录仪在AF管理中的作用。
